Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $1,507,000.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $75.35, for a total value of $1,507,000.00. Following the sale, the chief executive officer owned 733,719 shares in the company, valued at $55,285,726.65. This trade represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Helen Torley also recently made the following trade(s):

• On Friday, October 3rd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $69.03, for a total value of $1,380,600.00.
• On Wednesday, September 3rd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $74.44, for a total value of $1,488,800.00.
• On Tuesday, August 12th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $63.51, for a total value of $1,270,200.00.
• On Wednesday, July 9th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $56.43, for a total value of $1,128,600.00.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $68.98 on Monday. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36. The firm has a fifty day moving average of $70.45 and a 200 day moving average of $61.93. The firm has a market cap of $8.07 billion, a PE ratio of 15.78, a PEG ratio of 0.37 and a beta of 1.16. Halozyme Therapeutics, Inc. has a one year low of $42.01 and a one year high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The business had revenue of $325.72 million for the quarter, compared to analyst estimates of $282.66 million. During the same quarter last year, the business earned $0.91 earnings per share. The company’s revenue for the quarter was up 40.8% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Institutional Trading of Halozyme Therapeutics

Several hedge funds have recently added to or reduced their stakes in HALO. Wealth Preservation Advisors LLC acquired a new stake in shares of Halozyme Therapeutics in the 1st quarter valued at $32,000. Newbridge Financial Services Group Inc. acquired a new stake in shares of Halozyme Therapeutics in the 2nd quarter valued at about $32,000. SVB Wealth LLC acquired a new stake in shares of Halozyme Therapeutics in the first quarter valued at approximately $33,000. Bessemer Group Inc. grew its position in shares of Halozyme Therapeutics by 62.9% during the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 207 shares during the last quarter. Finally, Employees Retirement System of Texas acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at $34,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on HALO shares. JPMorgan Chase & Co. raised their target price on Halozyme Therapeutics from $60.00 to $63.00 and gave the company a “neutral” rating in a research report on Thursday, August 7th. Wall Street Zen lowered Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, September 5th. Benchmark upped their target price on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. The Goldman Sachs Group started coverage on shares of Halozyme Therapeutics in a research report on Thursday, July 10th. They issued a “neutral” rating and a $55.00 target price for the company. Finally, Morgan Stanley boosted their price target on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the stock an “overweight” rating in a research report on Monday, August 18th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $70.44.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.